Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Strategic Research Report

Scope of the Report

The global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market size is predicted to grow from US$ 4,738 million in 2025 to US$ 18,506 million in 2032; it is expected to grow at a CAGR of 21.6% from 2026 to 2032.

Non-steroidal androgen receptor inhibitors (NSARIs) are a class of oral small-molecule drugs that competitively bind to the androgen receptor (AR), inhibiting its nuclear translocation and transcriptional activity without possessing a steroidal structure; they selectively block androgen signaling pathways that drive prostate cancer progression and represent a core component of endocrine therapy for prostate cancer; the class has evolved from first-generation agents (e.g., bicalutamide) to second-generation high-affinity inhibitors such as Enzalutamide, Apalutamide, and Darolutamide, with continuous improvements in efficacy, resistance management, and safety profile, primarily indicated for nmCRPC and mHSPC and typically used in combination with androgen deprivation therapy (ADT).The global market for non-steroidal androgen receptor inhibitors is estimated at USD 4.8 billion in 2025, with a projected CAGR of approximately 20.85% from 2025 to 2030, corresponding to an annual treated patient population of about 500,000–600,000, driven by increasing penetration in nmCRPC, mCRPC, and mHSPC. Nominal capacity from the global high-potency small-molecule API network is sufficient to meet demand, and capacity does not constitute a constraint. Average treatment cost per patient per year is approximately USD 90,000–100,000 in the U.S., USD 50,000–70,000 in Europe, and USD 15,000–20,000 in China post-reimbursement negotiations, resulting in a weighted average of about USD 65,000 per patient per year, with a blended gross margin of roughly 85–90%.

Downstream demand is concentrated in the prostate cancer treatment pathway within oncology (nmCRPC → mCRPC → mHSPC). The value chain upstream consists of high-potency APIs and key intermediates synthesized via multi-step heterocyclic processes; midstream commercialization is led by originator companies (Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, and Bayer AG/Orion Corporation); downstream channels consist of hospitals and oncology specialty clinics. The global industry structure is characterized by “originator oligopoly + guideline-driven adoption + patent protection,” with primary competition from Enzalutamide, Apalutamide, and Darolutamide. The core compound patent of Darolutamide is expected to expire around 2030, but indication, formulation, and regional patent extensions may prolong actual market exclusivity to 2032–2035. Overall, the market is in the late growth stage, driven primarily by indication expansion and an increasing aging patient population, with key uncertainty arising from post-patent generic entry and reimbursement pressure.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market?

What factors are driving Non-steroidal Androgen Receptor Inhibitors（NSARIs） market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Non-steroidal Androgen Receptor Inhibitors（NSARIs） market opportunities vary by end market size?

How does Non-steroidal Androgen Receptor Inhibitors（NSARIs） break out by Type, by Application?

This report presents a comprehensive overview of the global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Enzalutamide
• Apalutamide
• Darolutamide
• Bicalutamide
• Nilutamide

Segment by Molecular

• High BBB Penetration
• Low BBB Penetration

Segment by Application

• nmCRPC
• mCRPC
• mHSPC
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in nmCRPC, mCRPC, mHSPC evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact